Insights Into Acute Myeloid Leukemia (AML) Southeast
Perspectives on management of newly diagnosed and relapsed/refractory AML
Southeast – June 22, 2020
Faculty Chair
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
REPORT SNAPSHOT
- The objective of the report is to gain advisors’ perspectives on the management of newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML)
- A moderated, virtual roundtable discussion focusing on treatment of AML was held on June 22, 2020
- Insights on the following AML therapies were obtained: azacitidine, cytarabine and daunorubicin (ie, 7+3), decitabine, ivosidenib, enasidenib, gemtuzumab ozogamicin, gilteritinib, liposomal daunorubicin and cytarabine, midostaurin, sorafenib, venetoclax, and glasdegib
- Data collection was accomplished through use of audience response system (ARS) questioning and in-depth moderated discussion
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Disease state and data presentations were developed in conjunction with Dr Naval Daver from MD Anderson Cancer Center
- The group of advisors comprised of community oncologists from the Southeast
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
